APA (7th ed.) Citation

Smitherman, T. A., Tietjen, G. E., Schuh, K., Skljarevski, V., Lipsius, S., D’Souza, D. N., & Pearlman, E. M. (2020). Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 Studies. Headache, 60(10), 2202-2219. https://doi.org/10.1111/head.13970

Chicago Style (17th ed.) Citation

Smitherman, Todd A., Gretchen E. Tietjen, Kory Schuh, Vladimir Skljarevski, Sarah Lipsius, Deborah N. D’Souza, and Eric M. Pearlman. "Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety And/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 Studies." Headache 60, no. 10 (2020): 2202-2219. https://doi.org/10.1111/head.13970.

MLA (9th ed.) Citation

Smitherman, Todd A., et al. "Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety And/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 Studies." Headache, vol. 60, no. 10, 2020, pp. 2202-2219, https://doi.org/10.1111/head.13970.